{"id":2374,"date":"2024-08-14T14:40:29","date_gmt":"2024-08-14T17:40:29","guid":{"rendered":"https:\/\/mbinitiative.org\/?p=2374"},"modified":"2025-09-01T18:02:15","modified_gmt":"2025-09-01T21:02:15","slug":"testes-clinicos-aprovados","status":"publish","type":"post","link":"https:\/\/mbinitiative.org\/pt\/testes-clinicos-aprovados\/","title":{"rendered":"Ensaios cl\u00ednicos aprovados \u2014 e iniciados \u2014 em tempo recorde"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Em apenas dois anos e meio, a MBI alcan\u00e7ou um de seus objetivos mais importantes: dois novos ensaios cl\u00ednicos foram aprovados para potenciais tratamentos de meduloblastoma recorrente do Grupo 4. Ambos s\u00e3o liderados por pesquisadores da Universidade da Fl\u00f3rida e financiados pela MBI, o Dr. Duane Mitchell e o Dr. Elias Sayour.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cada um representa o primeiro ensaio em humanos de seu tipo: <\/span><\/p>\n<p><span style=\"font-weight: 400;\">O estudo 1 \u2013 tamb\u00e9m chamado de MATCHPOINT \u2013 ataca os tumores de duas maneiras: \n\n1) Treina as c\u00e9lulas do pr\u00f3prio paciente para identificar e destruir as c\u00e9lulas cancer\u00edgenas;\n2)Utiliza um medicamento adicional para eliminar o sistema de defesa do tumor. <\/span><span style=\"font-weight: 400;\">O MATCHPOINT j\u00e1 inscreveu seu primeiro paciente e planeja admitir 12 pacientes nos pr\u00f3ximos dois anos.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">O estudo 2 ir\u00e1 testar uma vacina de mRNA \u2013 semelhante \u00e0 vacina contra a COVID-19, mas mais personalizada porque utiliza as c\u00e9lulas do pr\u00f3prio paciente. Nanotecnologia \u00e9 usada para criar a vacina. Uma vez injetada, a vacina gera uma resposta imune direcionada para destruir os tumores.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">O meduloblastoma recorrente, em qualquer forma, \u00e9 fatal\u201d, disse o Dr. Sayour. \u201cEstamos aqui para oferecer a esperan\u00e7a de que podemos fazer a diferen\u00e7a.\u201d\n\u201cO objetivo final \u00e9 curar crian\u00e7as com c\u00e2ncer cerebral e ver os tratamentos de imunoterapia se tornarem parte da primeira linha de tratamento, talvez evitando ou diminuindo a toxicidade dos tratamentos padr\u00e3o que usamos hoje\u201d, acrescentou o Dr. Mitchell.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Voc\u00ea pode ler a hist\u00f3ria completa sobre os dois ensaios aqui: <br \/><\/span><a href=\"https:\/\/mbi.ufl.edu\/2024\/06\/26\/uf-researchers-to-test-novel-treatments-for-medulloblastoma\/\" target=\"_blank\" rel=\"noopener\">https:\/\/mbi.ufl.edu\/2024\/06\/26\/uf-researchers-to-test-novel-treatments-for-medulloblastoma\/.<\/a><\/p>\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Os Drs. Duane Mitchell e Elias Sayour do Cons\u00f3rcio Cur grupo 4 receberam aprova\u00e7\u00e3o da Administra\u00e7\u00e3o de Alimentos e Medicamentos (FDA) dos EUA para testar\u2026<\/p>","protected":false},"author":4,"featured_media":2376,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[174,224,223,222,173],"class_list":["post-2374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sem-categoria","tag-mbi","tag-meduloblastoma-grupo-4","tag-terapias-experimentais","tag-testes-clinicos","tag-the-medulloblastoma-initiative"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CLINICAL TRIALS APPROVED! | The Medulloblastoma Initiative<\/title>\n<meta name=\"description\" content=\"Drs. Duane Mitchell and Elias Sayour have received approval to conduct experimental testing in pioneering clinical trials for Group 4 medulloblastoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mbinitiative.org\/pt\/testes-clinicos-aprovados\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CLINICAL TRIALS APPROVED! | The Medulloblastoma Initiative\" \/>\n<meta property=\"og:description\" content=\"Drs. Duane Mitchell and Elias Sayour have received approval to conduct experimental testing in pioneering clinical trials for Group 4 medulloblastoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mbinitiative.org\/pt\/testes-clinicos-aprovados\/\" \/>\n<meta property=\"og:site_name\" content=\"The Medulloblastoma Initiative\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/themedulloblastomainitiative\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-14T17:40:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T21:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MBI\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"MBI\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/\"},\"author\":{\"name\":\"MBI\",\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/person\/466abe8aeac08de69ff51a723b647b7f\"},\"headline\":\"Trials approved \u2014 and starting \u2014 in record\u00a0time\",\"datePublished\":\"2024-08-14T17:40:29+00:00\",\"dateModified\":\"2025-09-01T21:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/\"},\"wordCount\":236,\"publisher\":{\"@id\":\"https:\/\/mbinitiative.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png\",\"keywords\":[\"MBI\",\"meduloblastoma grupo 4\",\"terapias experimentais\",\"testes cl\u00ednicos\",\"the medulloblastoma initiative\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/\",\"url\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/\",\"name\":\"CLINICAL TRIALS APPROVED! | The Medulloblastoma Initiative\",\"isPartOf\":{\"@id\":\"https:\/\/mbinitiative.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png\",\"datePublished\":\"2024-08-14T17:40:29+00:00\",\"dateModified\":\"2025-09-01T21:02:15+00:00\",\"description\":\"Drs. Duane Mitchell and Elias Sayour have received approval to conduct experimental testing in pioneering clinical trials for Group 4 medulloblastoma.\",\"breadcrumb\":{\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mbinitiative.org\/clinical-trails-approved\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage\",\"url\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png\",\"contentUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png\",\"width\":1600,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mbinitiative.org\/clinical-trails-approved\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/mbinitiative.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trials approved \u2014 and starting \u2014 in record\u00a0time\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mbinitiative.org\/#website\",\"url\":\"https:\/\/mbinitiative.org\/\",\"name\":\"The Medulloblastoma Initiative\",\"description\":\"Cura do Meduloblastoma Infantil\",\"publisher\":{\"@id\":\"https:\/\/mbinitiative.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mbinitiative.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mbinitiative.org\/#organization\",\"name\":\"The Medulloblastoma Initiative\",\"url\":\"https:\/\/mbinitiative.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png\",\"contentUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png\",\"width\":354,\"height\":168,\"caption\":\"The Medulloblastoma Initiative\"},\"image\":{\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/themedulloblastomainitiative\",\"https:\/\/www.instagram.com\/medulloblastomainitiative\/\",\"https:\/\/www.linkedin.com\/company\/medulloblastomainitiative\/\",\"https:\/\/www.youtube.com\/@mbinitiative\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/person\/466abe8aeac08de69ff51a723b647b7f\",\"name\":\"MBI\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6446aa8591e99bf1553d89bc19db5af72fd25b4c6593ea37fd3dae05f7f06bb2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6446aa8591e99bf1553d89bc19db5af72fd25b4c6593ea37fd3dae05f7f06bb2?s=96&d=mm&r=g\",\"caption\":\"MBI\"},\"url\":\"https:\/\/mbinitiative.org\/pt\/author\/mbi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TESTES CL\u00cdNICOS APROVADOS! | The Medulloblastoma Initiative","description":"Os Drs. Duane Mitchell e Elias Sayour, do Cure Group 4 Consortium, receberam aprova\u00e7\u00e3o da Food and Drug Administration (FDA) dos EUA para testar duas novas terapias experimentais em ensaios cl\u00ednicos pioneiros para o meduloblastoma do Grupo 4.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mbinitiative.org\/pt\/testes-clinicos-aprovados\/","og_locale":"pt_BR","og_type":"article","og_title":"CLINICAL TRIALS APPROVED! | The Medulloblastoma Initiative","og_description":"Drs. Duane Mitchell and Elias Sayour have received approval to conduct experimental testing in pioneering clinical trials for Group 4 medulloblastoma.","og_url":"https:\/\/mbinitiative.org\/pt\/testes-clinicos-aprovados\/","og_site_name":"The Medulloblastoma Initiative","article_publisher":"https:\/\/www.facebook.com\/themedulloblastomainitiative","article_published_time":"2024-08-14T17:40:29+00:00","article_modified_time":"2025-09-01T21:02:15+00:00","og_image":[{"width":1600,"height":900,"url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png","type":"image\/png"}],"author":"MBI","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"MBI","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#article","isPartOf":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/"},"author":{"name":"MBI","@id":"https:\/\/mbinitiative.org\/#\/schema\/person\/466abe8aeac08de69ff51a723b647b7f"},"headline":"Trials approved \u2014 and starting \u2014 in record\u00a0time","datePublished":"2024-08-14T17:40:29+00:00","dateModified":"2025-09-01T21:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/"},"wordCount":236,"publisher":{"@id":"https:\/\/mbinitiative.org\/#organization"},"image":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png","keywords":["MBI","meduloblastoma grupo 4","terapias experimentais","testes cl\u00ednicos","the medulloblastoma initiative"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/","url":"https:\/\/mbinitiative.org\/clinical-trails-approved\/","name":"TESTES CL\u00cdNICOS APROVADOS! | The Medulloblastoma Initiative","isPartOf":{"@id":"https:\/\/mbinitiative.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage"},"image":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png","datePublished":"2024-08-14T17:40:29+00:00","dateModified":"2025-09-01T21:02:15+00:00","description":"Os Drs. Duane Mitchell e Elias Sayour, do Cure Group 4 Consortium, receberam aprova\u00e7\u00e3o da Food and Drug Administration (FDA) dos EUA para testar duas novas terapias experimentais em ensaios cl\u00ednicos pioneiros para o meduloblastoma do Grupo 4.","breadcrumb":{"@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mbinitiative.org\/clinical-trails-approved\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#primaryimage","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2024\/08\/Mitchell_Sayour.png","width":1600,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/mbinitiative.org\/clinical-trails-approved\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/mbinitiative.org\/"},{"@type":"ListItem","position":2,"name":"Trials approved \u2014 and starting \u2014 in record\u00a0time"}]},{"@type":"WebSite","@id":"https:\/\/mbinitiative.org\/#website","url":"https:\/\/mbinitiative.org\/","name":"(The Medulloblastoma Initiative)","description":"Cura do Meduloblastoma Infantil","publisher":{"@id":"https:\/\/mbinitiative.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mbinitiative.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/mbinitiative.org\/#organization","name":"(The Medulloblastoma Initiative)","url":"https:\/\/mbinitiative.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","width":354,"height":168,"caption":"The Medulloblastoma Initiative"},"image":{"@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/themedulloblastomainitiative","https:\/\/www.instagram.com\/medulloblastomainitiative\/","https:\/\/www.linkedin.com\/company\/medulloblastomainitiative\/","https:\/\/www.youtube.com\/@mbinitiative"]},{"@type":"Person","@id":"https:\/\/mbinitiative.org\/#\/schema\/person\/466abe8aeac08de69ff51a723b647b7f","name":"MBI","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6446aa8591e99bf1553d89bc19db5af72fd25b4c6593ea37fd3dae05f7f06bb2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6446aa8591e99bf1553d89bc19db5af72fd25b4c6593ea37fd3dae05f7f06bb2?s=96&d=mm&r=g","caption":"MBI"},"url":"https:\/\/mbinitiative.org\/pt\/author\/mbi\/"}]}},"_links":{"self":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/posts\/2374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/comments?post=2374"}],"version-history":[{"count":43,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/posts\/2374\/revisions"}],"predecessor-version":[{"id":6023,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/posts\/2374\/revisions\/6023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/media\/2376"}],"wp:attachment":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/media?parent=2374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/categories?post=2374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/tags?post=2374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}